Sponsor content
44 result(s) found, displaying 21 to 30
-
Australian public assessment report (AusPar)Spikevax XBB.1.5 (andusomeran) has been approved for the prevention of COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older.
-
Australian public assessment report (AusPar)Spikevax (Elasomeran/davesomeran), a vaccine, has transitioned from provisional to full registration. Spikevax is for the prevention of coronavirus disease 2019 caused by SARS-CoV-2.
-
Australian public assessment report (AusPar)New AusPAR for Spikevax (elasomeran) for the prevention of COVID-19 caused by SARS-CoV-2.
-
Designation or determinationPriority review
-
Australian public assessment report (AusPar)AusPAR for SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5 (elasomeran/davesomeran) as booster dose for active immunisation to prevent COVID-19
-
Prescription medicine decision summaryapproved to prevent coronavirus disease 2019 (COVID-19)
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SPIKEVAX (elasomeran) COVID-19 VACCINE 0.2 mg/mL suspension for injection vial.
-
Prescription medicine registrationActive ingredients: elasomeran, davesomeran.
-
Australian public assessment report (AusPar)AusPAR for SPIKEVAX COVID-19 VACCINE (elasomeran) as booster in 12 to 17 years of age for prevention of COVID-19
-
Designation or determinationProvisional determination